Ozempic and Wegovy Lawsuit Lawyer

Update, February 2026: MDL case numbers continue to grow. There were 3,100 pending actions in the GLP-1 MDL.

Update, December 2025: The U.S. Judicial Panel for Multidistrict Litigation (JPML) formed another GLP-1 MDL, transferring cases involving claims of NAION (non-arteritic anterior ischemic optic neuropathy) to an MDL named In Re: Glucagon-like Peptide-1 Receptor Agonists (GLP-1 RAs) Non-Arteritic Anterior Ischemic Optic Neuropathy Products Liability Litigation, MDL 3163.  This MDL was also assigned to Judge Karen S. Marston in the Eastern District of Pennsylvania, who is presiding over the GLP-1 MDL formed for patients suffering from gastrointestinal-related injuries. 

Update, November 2025: Another 100-plus cases were added to the MDL, bringing the total number of pending actions to over 2,900.

Update, August 2025: The number of active claims in the MDL grew to over 2,000.

Update, June 2025: A group of 21 plaintiffs who suffered NAION after taking the medications asked the state court to consolidate their cases against Novo Nordisk into a multicounty litigation in the State of New Jersey. 

Update, April 2025:

• Another study connected GLP-1 use to vision loss based on FDA complaints. However, as of May 5, 2025, no warnings of this connection are currently listed on GLP-1 RA product labels.
• A 62-year-old man who started taking Ozempic to manage his diabetes developed NAION and lost vision in both eyes filed a lawsuit against Novo Nordisk.
• A woman who used Ozempic to manage her type 2 diabetes also suffered permanent vision loss, diagnosed as NAION, filed a lawsuit in New Jersey federal court.

Update, March 2025: Filed cases continue to rise, with over 1,500 pending in the MDL. 

Update, February 2025:

• A JAMA Ophthalmology study found two new eye complications linked to GLP-1 RAs: bilateral papillitis and paracentral acute middle maculopathy. Both conditions are similar to NAION in that they involve the optic nerve, but unlike NAION, they are treatable and reversible.
• A large study of over 37 million patientsreported “further evidence of an association between semaglutide and NAION.”
• A separate study reported that most patients using GLP-1s for weight loss stop within a year. The study cited cost and side effects as reasons for their discontinuation.

Update, January 2025: By the end of 2024, more than 27,000 adverse events (side effects, reactions, hospitalizations) involving Ozempic had been reported to the FDA’s Adverse Event Reporting System (FAERS).  Note: FAERS is intended to help identify safety concerns, but reported adverse events alone are not an indicator of a medical product’s safety profile.

Update, December 2024:

• Danish researchers published a five-year longitudinal study that confirmed earlier findings linking semaglutide to an increased risk of vision loss. According to the study, use of the active ingredient commonly found in once-weekly Ozempic and Wegovy more than doubled the risk of losing vision. The study stated, “as optic neuropathies are untreatable and irreversible, particular care should be given to avoid onset. For upcoming studies, it would be important to identify any potential high-risk subgroups as well as assess whether the elevated risk of NAION is a drug class effect or a specific finding for subcutaneously administered semaglutide.”
• The GLP-1 MDL continued to grow, bringing the total number of cases in the docket to 1,300.
• Deep vein thrombosis and blood clot cases will not be included as injuries in the GLP-1 MDL.

Update, November 2024: 

• The FDA has updated the Ozempic label to include a new warning about an increased risk of pulmonary aspiration. The agency states that some Ozempic users might experience this during general anesthesia or deep sedation, even if they follow preoperative fasting guidelines.
• The Adverse Reaction section of the label includes: “Pulmonary aspiration has occurred in patients receiving GLP-1 receptor agonists undergoing elective surgeries or procedures requiring general anesthesia or deep sedation.”

Update, July 2024: A study has linked use of semaglutide-containing drugs like Ozempic and Wegovy to a serious eye condition which can cause irreversible vision loss. Non-arteritic anterior ischemic optic neuropathy (NAION) is a condition that affects the optic nerve. In individuals with NAION, blood flow to the optic nerve gets reduced or blocked, leading to sudden vision loss. The researchers found that patients treating diabetes with semaglutide at four times higher risk for developing NAION. Patients using semaglutide for weight loss had a seven-times higher risk of developing NAION.

Update, September 2023: The FDA added “Gastrointestinal: ileus” to the “Postmarketing Experience” section of Ozempic’s label.  Ileus is a non-mechanical, functional disruption of bowel movement involving a blockage of the intestines.